Loading…

Human menopausal and pregnant mare serum gonadotrophins in murine superovulation regimens for transgenic applications

Superovulation is a fundamental procedure for generating transgenic rodents. While various methods exist, zygote yield/quality remain suboptimal, making these techniques open to refinement. All require a follicle stimulating and a luteinising effect. The former can be induced by pregnant mare serum...

Full description

Saved in:
Bibliographic Details
Published in:Theriogenology 2007-05, Vol.67 (8), p.1409-1413
Main Authors: Brooke, D.A., Orsi, N.M., Ainscough, J.F.X., Holwell, S.E., Markham, A.F., Coletta, P.L.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c384t-bd214fc86e1ae4becc9a692098ab88d72b2aac9747376aa98eb7ce418ae97c1a3
cites cdi_FETCH-LOGICAL-c384t-bd214fc86e1ae4becc9a692098ab88d72b2aac9747376aa98eb7ce418ae97c1a3
container_end_page 1413
container_issue 8
container_start_page 1409
container_title Theriogenology
container_volume 67
creator Brooke, D.A.
Orsi, N.M.
Ainscough, J.F.X.
Holwell, S.E.
Markham, A.F.
Coletta, P.L.
description Superovulation is a fundamental procedure for generating transgenic rodents. While various methods exist, zygote yield/quality remain suboptimal, making these techniques open to refinement. All require a follicle stimulating and a luteinising effect. The former can be induced by pregnant mare serum gonadotrophin (PMSG) or other compounds like human menopausal gonadotrophin (HMG). While HMG can double zygote yield compared to PMSG, no study has compared their effects on embryo quality. Embryo yield could also be increased with PMSG: timing administration at estrus may further improve follicular recruitment. This study compared: (i) the efficacy of HMG/PMSG for producing viable embryos for microinjection; and (ii) the effect of HMG/PMSG administration at estrus on embryo yield. Whitten effect-induced estrous C57/Bl6xCBA F 1 hybrid mice were superovulated as follows: PMSG (day 1; 5 IU intraperitoneally) or HMG (days 1 and 2; 1 IU intramuscularly); all received human chorionic gonadotrophin (hCG) on day 3 (5 IU, intraperitoneally). Zygotes were retrieved following mating, morphologically assessed and microinjected with innocuous ZhAT1R construct (expressing LacZ reporter and human angiotensin II type 1 receptor) before transfer to pseudopregnant recipients. Pups were tested for the transgene by Southern blot. Neither HMG nor PMSG proved superior in improving embryo yield, morphology and short-term post-microinjection survival. However, HMG group micromanipulated embryos all failed to establish a pregnancy/generate transgenic pups, unlike their PMSG counterparts. While HMG can be used for superovulation, it appears to increase embryo vulnerability to the long-term effects of microinjection. Furthermore, the embryo yields associated with HMG can be replicated by timing PMSG injection to coincide with Whitten effect-induced estrus.
doi_str_mv 10.1016/j.theriogenology.2007.03.008
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70411696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0093691X07000970</els_id><sourcerecordid>70411696</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-bd214fc86e1ae4becc9a692098ab88d72b2aac9747376aa98eb7ce418ae97c1a3</originalsourceid><addsrcrecordid>eNqNkE1r3DAQhkVpabZp_0LRIfRmV7KMPiCXEJKmEMilhd7EWJ7daLElR7IC-fdRsguht5x0mOd9R_MQcsZZyxmXP_fteo_Jxx2GOMXdU9sxplomWsb0B7LhWplGdIJ_JBvGjGik4f9OyJec94wxISX_TE646mtKmA0pN2WGQOdatkDJMFEII10S7gKElc6QkGZMZaa7GGCMa4rLvQ-Z-hoqyYc6Lgum-FgmWH0MtEZ9rct0GxNdE4Rcf-odhWWZvHtl8lfyaQtTxm_H95T8vb76c3nT3N79-n15cds4ofu1GcaO91unJXLAfkDnDEjTMaNh0HpU3dABOKN6JZQEMBoH5bDnGtAox0Gckh-H3iXFh4J5tbPPDqcJAsaSrWI959LICp4fQJdizgm3dkm-Hv9kObMv2u3e_q_dvmi3TNiqvca_H_eUYcbxLXz0XIHrA4D12kePyWbnMTgcfUK32jH69216Bp8iod4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70411696</pqid></control><display><type>article</type><title>Human menopausal and pregnant mare serum gonadotrophins in murine superovulation regimens for transgenic applications</title><source>ScienceDirect Journals</source><creator>Brooke, D.A. ; Orsi, N.M. ; Ainscough, J.F.X. ; Holwell, S.E. ; Markham, A.F. ; Coletta, P.L.</creator><creatorcontrib>Brooke, D.A. ; Orsi, N.M. ; Ainscough, J.F.X. ; Holwell, S.E. ; Markham, A.F. ; Coletta, P.L.</creatorcontrib><description>Superovulation is a fundamental procedure for generating transgenic rodents. While various methods exist, zygote yield/quality remain suboptimal, making these techniques open to refinement. All require a follicle stimulating and a luteinising effect. The former can be induced by pregnant mare serum gonadotrophin (PMSG) or other compounds like human menopausal gonadotrophin (HMG). While HMG can double zygote yield compared to PMSG, no study has compared their effects on embryo quality. Embryo yield could also be increased with PMSG: timing administration at estrus may further improve follicular recruitment. This study compared: (i) the efficacy of HMG/PMSG for producing viable embryos for microinjection; and (ii) the effect of HMG/PMSG administration at estrus on embryo yield. Whitten effect-induced estrous C57/Bl6xCBA F 1 hybrid mice were superovulated as follows: PMSG (day 1; 5 IU intraperitoneally) or HMG (days 1 and 2; 1 IU intramuscularly); all received human chorionic gonadotrophin (hCG) on day 3 (5 IU, intraperitoneally). Zygotes were retrieved following mating, morphologically assessed and microinjected with innocuous ZhAT1R construct (expressing LacZ reporter and human angiotensin II type 1 receptor) before transfer to pseudopregnant recipients. Pups were tested for the transgene by Southern blot. Neither HMG nor PMSG proved superior in improving embryo yield, morphology and short-term post-microinjection survival. However, HMG group micromanipulated embryos all failed to establish a pregnancy/generate transgenic pups, unlike their PMSG counterparts. While HMG can be used for superovulation, it appears to increase embryo vulnerability to the long-term effects of microinjection. Furthermore, the embryo yields associated with HMG can be replicated by timing PMSG injection to coincide with Whitten effect-induced estrus.</description><identifier>ISSN: 0093-691X</identifier><identifier>EISSN: 1879-3231</identifier><identifier>DOI: 10.1016/j.theriogenology.2007.03.008</identifier><identifier>PMID: 17420039</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Blotting, Southern ; Embryo Transfer - veterinary ; Female ; Gene Transfer Techniques - veterinary ; Gonadotrophin ; Gonadotropins, Equine - administration &amp; dosage ; Humans ; Menotropins - administration &amp; dosage ; Mice ; Mice, Inbred C57BL ; Mice, Inbred CBA ; Mice, Transgenic ; Microinjections - veterinary ; Mouse ; Pregnancy ; Pseudopregnancy - veterinary ; Receptor, Angiotensin, Type 1 - genetics ; Superovulation ; Tissue and Organ Harvesting - veterinary ; Transgenes ; Transgenics ; Zygote</subject><ispartof>Theriogenology, 2007-05, Vol.67 (8), p.1409-1413</ispartof><rights>2007 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-bd214fc86e1ae4becc9a692098ab88d72b2aac9747376aa98eb7ce418ae97c1a3</citedby><cites>FETCH-LOGICAL-c384t-bd214fc86e1ae4becc9a692098ab88d72b2aac9747376aa98eb7ce418ae97c1a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17420039$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brooke, D.A.</creatorcontrib><creatorcontrib>Orsi, N.M.</creatorcontrib><creatorcontrib>Ainscough, J.F.X.</creatorcontrib><creatorcontrib>Holwell, S.E.</creatorcontrib><creatorcontrib>Markham, A.F.</creatorcontrib><creatorcontrib>Coletta, P.L.</creatorcontrib><title>Human menopausal and pregnant mare serum gonadotrophins in murine superovulation regimens for transgenic applications</title><title>Theriogenology</title><addtitle>Theriogenology</addtitle><description>Superovulation is a fundamental procedure for generating transgenic rodents. While various methods exist, zygote yield/quality remain suboptimal, making these techniques open to refinement. All require a follicle stimulating and a luteinising effect. The former can be induced by pregnant mare serum gonadotrophin (PMSG) or other compounds like human menopausal gonadotrophin (HMG). While HMG can double zygote yield compared to PMSG, no study has compared their effects on embryo quality. Embryo yield could also be increased with PMSG: timing administration at estrus may further improve follicular recruitment. This study compared: (i) the efficacy of HMG/PMSG for producing viable embryos for microinjection; and (ii) the effect of HMG/PMSG administration at estrus on embryo yield. Whitten effect-induced estrous C57/Bl6xCBA F 1 hybrid mice were superovulated as follows: PMSG (day 1; 5 IU intraperitoneally) or HMG (days 1 and 2; 1 IU intramuscularly); all received human chorionic gonadotrophin (hCG) on day 3 (5 IU, intraperitoneally). Zygotes were retrieved following mating, morphologically assessed and microinjected with innocuous ZhAT1R construct (expressing LacZ reporter and human angiotensin II type 1 receptor) before transfer to pseudopregnant recipients. Pups were tested for the transgene by Southern blot. Neither HMG nor PMSG proved superior in improving embryo yield, morphology and short-term post-microinjection survival. However, HMG group micromanipulated embryos all failed to establish a pregnancy/generate transgenic pups, unlike their PMSG counterparts. While HMG can be used for superovulation, it appears to increase embryo vulnerability to the long-term effects of microinjection. Furthermore, the embryo yields associated with HMG can be replicated by timing PMSG injection to coincide with Whitten effect-induced estrus.</description><subject>Animals</subject><subject>Blotting, Southern</subject><subject>Embryo Transfer - veterinary</subject><subject>Female</subject><subject>Gene Transfer Techniques - veterinary</subject><subject>Gonadotrophin</subject><subject>Gonadotropins, Equine - administration &amp; dosage</subject><subject>Humans</subject><subject>Menotropins - administration &amp; dosage</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Inbred CBA</subject><subject>Mice, Transgenic</subject><subject>Microinjections - veterinary</subject><subject>Mouse</subject><subject>Pregnancy</subject><subject>Pseudopregnancy - veterinary</subject><subject>Receptor, Angiotensin, Type 1 - genetics</subject><subject>Superovulation</subject><subject>Tissue and Organ Harvesting - veterinary</subject><subject>Transgenes</subject><subject>Transgenics</subject><subject>Zygote</subject><issn>0093-691X</issn><issn>1879-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqNkE1r3DAQhkVpabZp_0LRIfRmV7KMPiCXEJKmEMilhd7EWJ7daLElR7IC-fdRsguht5x0mOd9R_MQcsZZyxmXP_fteo_Jxx2GOMXdU9sxplomWsb0B7LhWplGdIJ_JBvGjGik4f9OyJec94wxISX_TE646mtKmA0pN2WGQOdatkDJMFEII10S7gKElc6QkGZMZaa7GGCMa4rLvQ-Z-hoqyYc6Lgum-FgmWH0MtEZ9rct0GxNdE4Rcf-odhWWZvHtl8lfyaQtTxm_H95T8vb76c3nT3N79-n15cds4ofu1GcaO91unJXLAfkDnDEjTMaNh0HpU3dABOKN6JZQEMBoH5bDnGtAox0Gckh-H3iXFh4J5tbPPDqcJAsaSrWI959LICp4fQJdizgm3dkm-Hv9kObMv2u3e_q_dvmi3TNiqvca_H_eUYcbxLXz0XIHrA4D12kePyWbnMTgcfUK32jH69216Bp8iod4</recordid><startdate>20070501</startdate><enddate>20070501</enddate><creator>Brooke, D.A.</creator><creator>Orsi, N.M.</creator><creator>Ainscough, J.F.X.</creator><creator>Holwell, S.E.</creator><creator>Markham, A.F.</creator><creator>Coletta, P.L.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070501</creationdate><title>Human menopausal and pregnant mare serum gonadotrophins in murine superovulation regimens for transgenic applications</title><author>Brooke, D.A. ; Orsi, N.M. ; Ainscough, J.F.X. ; Holwell, S.E. ; Markham, A.F. ; Coletta, P.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-bd214fc86e1ae4becc9a692098ab88d72b2aac9747376aa98eb7ce418ae97c1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Blotting, Southern</topic><topic>Embryo Transfer - veterinary</topic><topic>Female</topic><topic>Gene Transfer Techniques - veterinary</topic><topic>Gonadotrophin</topic><topic>Gonadotropins, Equine - administration &amp; dosage</topic><topic>Humans</topic><topic>Menotropins - administration &amp; dosage</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Inbred CBA</topic><topic>Mice, Transgenic</topic><topic>Microinjections - veterinary</topic><topic>Mouse</topic><topic>Pregnancy</topic><topic>Pseudopregnancy - veterinary</topic><topic>Receptor, Angiotensin, Type 1 - genetics</topic><topic>Superovulation</topic><topic>Tissue and Organ Harvesting - veterinary</topic><topic>Transgenes</topic><topic>Transgenics</topic><topic>Zygote</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brooke, D.A.</creatorcontrib><creatorcontrib>Orsi, N.M.</creatorcontrib><creatorcontrib>Ainscough, J.F.X.</creatorcontrib><creatorcontrib>Holwell, S.E.</creatorcontrib><creatorcontrib>Markham, A.F.</creatorcontrib><creatorcontrib>Coletta, P.L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Theriogenology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brooke, D.A.</au><au>Orsi, N.M.</au><au>Ainscough, J.F.X.</au><au>Holwell, S.E.</au><au>Markham, A.F.</au><au>Coletta, P.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human menopausal and pregnant mare serum gonadotrophins in murine superovulation regimens for transgenic applications</atitle><jtitle>Theriogenology</jtitle><addtitle>Theriogenology</addtitle><date>2007-05-01</date><risdate>2007</risdate><volume>67</volume><issue>8</issue><spage>1409</spage><epage>1413</epage><pages>1409-1413</pages><issn>0093-691X</issn><eissn>1879-3231</eissn><abstract>Superovulation is a fundamental procedure for generating transgenic rodents. While various methods exist, zygote yield/quality remain suboptimal, making these techniques open to refinement. All require a follicle stimulating and a luteinising effect. The former can be induced by pregnant mare serum gonadotrophin (PMSG) or other compounds like human menopausal gonadotrophin (HMG). While HMG can double zygote yield compared to PMSG, no study has compared their effects on embryo quality. Embryo yield could also be increased with PMSG: timing administration at estrus may further improve follicular recruitment. This study compared: (i) the efficacy of HMG/PMSG for producing viable embryos for microinjection; and (ii) the effect of HMG/PMSG administration at estrus on embryo yield. Whitten effect-induced estrous C57/Bl6xCBA F 1 hybrid mice were superovulated as follows: PMSG (day 1; 5 IU intraperitoneally) or HMG (days 1 and 2; 1 IU intramuscularly); all received human chorionic gonadotrophin (hCG) on day 3 (5 IU, intraperitoneally). Zygotes were retrieved following mating, morphologically assessed and microinjected with innocuous ZhAT1R construct (expressing LacZ reporter and human angiotensin II type 1 receptor) before transfer to pseudopregnant recipients. Pups were tested for the transgene by Southern blot. Neither HMG nor PMSG proved superior in improving embryo yield, morphology and short-term post-microinjection survival. However, HMG group micromanipulated embryos all failed to establish a pregnancy/generate transgenic pups, unlike their PMSG counterparts. While HMG can be used for superovulation, it appears to increase embryo vulnerability to the long-term effects of microinjection. Furthermore, the embryo yields associated with HMG can be replicated by timing PMSG injection to coincide with Whitten effect-induced estrus.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>17420039</pmid><doi>10.1016/j.theriogenology.2007.03.008</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0093-691X
ispartof Theriogenology, 2007-05, Vol.67 (8), p.1409-1413
issn 0093-691X
1879-3231
language eng
recordid cdi_proquest_miscellaneous_70411696
source ScienceDirect Journals
subjects Animals
Blotting, Southern
Embryo Transfer - veterinary
Female
Gene Transfer Techniques - veterinary
Gonadotrophin
Gonadotropins, Equine - administration & dosage
Humans
Menotropins - administration & dosage
Mice
Mice, Inbred C57BL
Mice, Inbred CBA
Mice, Transgenic
Microinjections - veterinary
Mouse
Pregnancy
Pseudopregnancy - veterinary
Receptor, Angiotensin, Type 1 - genetics
Superovulation
Tissue and Organ Harvesting - veterinary
Transgenes
Transgenics
Zygote
title Human menopausal and pregnant mare serum gonadotrophins in murine superovulation regimens for transgenic applications
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A35%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20menopausal%20and%20pregnant%20mare%20serum%20gonadotrophins%20in%20murine%20superovulation%20regimens%20for%20transgenic%20applications&rft.jtitle=Theriogenology&rft.au=Brooke,%20D.A.&rft.date=2007-05-01&rft.volume=67&rft.issue=8&rft.spage=1409&rft.epage=1413&rft.pages=1409-1413&rft.issn=0093-691X&rft.eissn=1879-3231&rft_id=info:doi/10.1016/j.theriogenology.2007.03.008&rft_dat=%3Cproquest_cross%3E70411696%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c384t-bd214fc86e1ae4becc9a692098ab88d72b2aac9747376aa98eb7ce418ae97c1a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70411696&rft_id=info:pmid/17420039&rfr_iscdi=true